[Research Advances of Immunotherapy of Exosome PD-L1 in Non-small Cell Lung Cancer]

Zhongguo Fei Ai Za Zhi. 2022 Sep 20;25(9):689-695. doi: 10.3779/j.issn.1009-3419.2022.102.33.
[Article in Chinese]

Abstract

Cancer immunotherapy is increasingly popular in the field of cancer treatment, and related research is emerging. For patients with non-small cell lung cancer (NSCLC), in recent years, immune checkpoint inhibitors (ICIs) represented by programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) immunosuppressants, have become one of the most promising treatments for malignant tumors. Immune checkpoint blockade therapy includes anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) mAb, anti-PD-1 mAb and anti-PD-L1 mAb, with the best-known number of PD-L1 immunotherapy. At present, ICIs have achieved very good therapeutic results in clinical treatment, but with less effective efficiency, so we hope to obtain higher therapeutic efficiency. In recent years, exosomal PD-L1 has played an important role in the progress of immunotherapy for NSCLC. This paper reviews the effects of tumor exosomal PD-L1 protein on the tumor microenvironment, the effect prediction of immunotherapy, and as novel therapeutic strategies for immunotherapy in NSCLC. .

【中文题目:外泌体PD-L1在非小细胞肺癌免疫治疗 的研究进展】 【中文摘要:肿瘤免疫疗法在当前癌症治疗领域中愈来愈受瞩目,相关研究也层出不穷。对于非小细胞肺癌(non-small cell lung cancer, NSCLC)患者来说,近些年来,以程序性死亡受体1(programmed cell death 1, PD-1)/程序性死亡配体1(programmed cell death ligand 1, PD-L1)免疫抑制剂为代表的免疫检查点抑制剂(immune checkpoint inhibitors, ICIs)已经成为治疗恶性肿瘤的一种最具前景的治疗方案。免疫检查点阻断治疗包括抗细胞毒T淋巴细胞相关抗原4(cytotoxic T lymphocyte-associated antigen 4, CTLA-4)单抗、抗PD-1单抗和抗PD-L1单抗,其中最被人熟知的为PD-L1免疫疗法。目前ICIs在临床治疗中取得了很不错的治疗效果,但有效率较低,因此我们希望获得更高的治疗有效率。近几年外泌体PD-L1在NSCLC免疫治疗中发挥了重要作用。本文就肿瘤外泌体PD-L1蛋白对肿瘤微环境的影响、预测免疫治疗效果以及作为NSCLC免疫治疗的新型治疗策略作一综述。 】 【中文关键词:外泌体;PD-L1;肺肿瘤;免疫治疗】.

Keywords: Exosome; Immunotherapy; Lung neoplasms; PD-L1.

Publication types

  • Review

MeSH terms

  • B7-H1 Antigen
  • CTLA-4 Antigen
  • Carcinoma, Non-Small-Cell Lung* / pathology
  • Exosomes* / pathology
  • Humans
  • Immune Checkpoint Inhibitors
  • Immunosuppressive Agents / therapeutic use
  • Immunotherapy / methods
  • Ligands
  • Lung Neoplasms* / pathology
  • Programmed Cell Death 1 Receptor
  • Tumor Microenvironment

Substances

  • B7-H1 Antigen
  • CTLA-4 Antigen
  • Immune Checkpoint Inhibitors
  • Immunosuppressive Agents
  • Ligands
  • Programmed Cell Death 1 Receptor